Selected research
Industry Research
Medicines for Alzheimer Disease Treatment Industry Research Report 2026
Market perspective
The global Medicines for Alzheimer Disease Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Medicines for Alzheimer Disease Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Medicines for Alzheimer Disease Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Medicines for Alzheimer Disease Treatment include Novartis AG, AbbVie Inc, Lupin Pharmaceuticals, Inc, Janssen Global Services, LLC, H. Lundbeck A/S, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC and Actiza Pharmaceutical Private Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Medicines for Alzheimer Disease Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medicines for Alzheimer Disease Treatment Market by Company
Novartis AG
AbbVie Inc
Lupin Pharmaceuticals, Inc
Janssen Global Services, LLC
H. Lundbeck A/S
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Company Limited
Amneal Pharmaceuticals LLC
Actiza Pharmaceutical Private Limited
AC Immune
Medicines for Alzheimer Disease Treatment Segment by Type
NMDA Receptor Antagonists
Cholinesterase Inhibitors
Medicines for Alzheimer Disease Treatment Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Medicines for Alzheimer Disease Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicines for Alzheimer Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medicines for Alzheimer Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicines for Alzheimer Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Medicines for Alzheimer Disease Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Medicines for Alzheimer Disease Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Medicines for Alzheimer Disease Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- NMDA Receptor Antagonists
- Cholinesterase Inhibitors
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Companies covered
- Novartis AG
- AbbVie Inc
- Lupin Pharmaceuticals, Inc
- Janssen Global Services, LLC
- H. Lundbeck A/S
- F. Hoffmann-La Roche Ltd
- Daiichi Sankyo Company Limited
- Amneal Pharmaceuticals LLC
- Actiza Pharmaceutical Private Limited
- AC Immune
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Medicines for Alzheimer Disease Treatment Market Size (2021-2032)
- 2.2.2 Global Medicines for Alzheimer Disease Treatment Sales (2021-2032)
- 2.2.3 Global Medicines for Alzheimer Disease Treatment Market Average Price (2021-2032)
- 2.3 Medicines for Alzheimer Disease Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 NMDA Receptor Antagonists
- 2.3.3 Cholinesterase Inhibitors
- 2.4 Medicines for Alzheimer Disease Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacy
- 2.4.3 Online Pharmacy
- 2.4.4 Retail Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Medicines for Alzheimer Disease Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Medicines for Alzheimer Disease Treatment Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Medicines for Alzheimer Disease Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Medicines for Alzheimer Disease Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Medicines for Alzheimer Disease Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Medicines for Alzheimer Disease Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Medicines for Alzheimer Disease Treatment, Product Type & Application
- 3.8 Global Manufacturers of Medicines for Alzheimer Disease Treatment, Established Date
- 3.9 Global Medicines for Alzheimer Disease Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 AbbVie Inc
- 4.2.1 AbbVie Inc Company Information
- 4.2.2 AbbVie Inc Business Overview
- 4.2.3 AbbVie Inc Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AbbVie Inc Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.2.5 AbbVie Inc Recent Developments
- 4.3 Lupin Pharmaceuticals, Inc
- 4.3.1 Lupin Pharmaceuticals, Inc Company Information
- 4.3.2 Lupin Pharmaceuticals, Inc Business Overview
- 4.3.3 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.3.5 Lupin Pharmaceuticals, Inc Recent Developments
- 4.4 Janssen Global Services, LLC
- 4.4.1 Janssen Global Services, LLC Company Information
- 4.4.2 Janssen Global Services, LLC Business Overview
- 4.4.3 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.4.5 Janssen Global Services, LLC Recent Developments
- 4.5 H. Lundbeck A/S
- 4.5.1 H. Lundbeck A/S Company Information
- 4.5.2 H. Lundbeck A/S Business Overview
- 4.5.3 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.5.5 H. Lundbeck A/S Recent Developments
- 4.6 F. Hoffmann-La Roche Ltd
- 4.6.1 F. Hoffmann-La Roche Ltd Company Information
- 4.6.2 F. Hoffmann-La Roche Ltd Business Overview
- 4.6.3 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.6.5 F. Hoffmann-La Roche Ltd Recent Developments
- 4.7 Daiichi Sankyo Company Limited
- 4.7.1 Daiichi Sankyo Company Limited Company Information
- 4.7.2 Daiichi Sankyo Company Limited Business Overview
- 4.7.3 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.7.5 Daiichi Sankyo Company Limited Recent Developments
- 4.8 Amneal Pharmaceuticals LLC
- 4.8.1 Amneal Pharmaceuticals LLC Company Information
- 4.8.2 Amneal Pharmaceuticals LLC Business Overview
- 4.8.3 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.8.5 Amneal Pharmaceuticals LLC Recent Developments
- 4.9 Actiza Pharmaceutical Private Limited
- 4.9.1 Actiza Pharmaceutical Private Limited Company Information
- 4.9.2 Actiza Pharmaceutical Private Limited Business Overview
- 4.9.3 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.9.5 Actiza Pharmaceutical Private Limited Recent Developments
- 4.10 AC Immune
- 4.10.1 AC Immune Company Information
- 4.10.2 AC Immune Business Overview
- 4.10.3 AC Immune Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AC Immune Medicines for Alzheimer Disease Treatment Product Portfolio
- 4.10.5 AC Immune Recent Developments
5 Global Medicines for Alzheimer Disease Treatment Market Scenario by Region
- 5.1 Global Medicines for Alzheimer Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021-2032
- 5.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021-2026
- 5.2.2 Global Medicines for Alzheimer Disease Treatment Sales by Region: 2027-2032
- 5.3 Global Medicines for Alzheimer Disease Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Medicines for Alzheimer Disease Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Medicines for Alzheimer Disease Treatment Revenue by Region: 2027-2032
- 5.4 North America Medicines for Alzheimer Disease Treatment Market Facts & Figures by Country
- 5.4.1 North America Medicines for Alzheimer Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 5.4.3 North America Medicines for Alzheimer Disease Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Medicines for Alzheimer Disease Treatment Market Facts & Figures by Country
- 5.5.1 Europe Medicines for Alzheimer Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Medicines for Alzheimer Disease Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Medicines for Alzheimer Disease Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Medicines for Alzheimer Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Medicines for Alzheimer Disease Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Medicines for Alzheimer Disease Treatment Market Facts & Figures by Country
- 5.7.1 South America Medicines for Alzheimer Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 5.7.3 South America Medicines for Alzheimer Disease Treatment Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Medicines for Alzheimer Disease Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Medicines for Alzheimer Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Medicines for Alzheimer Disease Treatment Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Medicines for Alzheimer Disease Treatment Sales by Type (2021-2032)
- 6.1.1 Global Medicines for Alzheimer Disease Treatment Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Medicines for Alzheimer Disease Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Medicines for Alzheimer Disease Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Medicines for Alzheimer Disease Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Medicines for Alzheimer Disease Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Medicines for Alzheimer Disease Treatment Sales by Application (2021-2032)
- 7.1.1 Global Medicines for Alzheimer Disease Treatment Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Medicines for Alzheimer Disease Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Medicines for Alzheimer Disease Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Medicines for Alzheimer Disease Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Medicines for Alzheimer Disease Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Medicines for Alzheimer Disease Treatment Value Chain Analysis
- 8.1.1 Medicines for Alzheimer Disease Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Medicines for Alzheimer Disease Treatment Production Mode & Process
- 8.2 Medicines for Alzheimer Disease Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Medicines for Alzheimer Disease Treatment Distributors
- 8.2.3 Medicines for Alzheimer Disease Treatment Customers
9 Global Medicines for Alzheimer Disease Treatment Analyzing Market Dynamics
- 9.1 Medicines for Alzheimer Disease Treatment Industry Trends
- 9.2 Medicines for Alzheimer Disease Treatment Industry Drivers
- 9.3 Medicines for Alzheimer Disease Treatment Industry Opportunities and Challenges
- 9.4 Medicines for Alzheimer Disease Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst